June 11, 2021 12:00 UTC
KB Home Announces the Grand Opening of Stewart Crossing, Its Latest New-home Community in a Prime Pierce County, Washington Location
KB Home Announces the Grand Opening of Stewart Crossing, Its Latest New-home Community in a Prime Pierce County, Washington Location June 11, 2021 12:00 UTC KB Home Announces the Grand Opening of Stewart Crossing, Its Latest New-home Community in a Prime Pierce County, Washington Location Homebuilder to offer personalized, new homes near Tacoma, priced from the $540,000s PUYALLUP, Wash.--(BUSINESS WIRE)-- KB Home (NYSE: KBH) today announced the grand opening of Stewart Crossing, a new, single-family home community in a desirable Pierce County, Washington location. Stewart Crossing is situated ten miles southeast of Tacoma in the historic city of Puyallup, offering convenient acc
June 11, 2021 11:30 UTC
Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis
Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis June 11, 2021 11:30 UTC Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq:INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for ruxolitinib cream for the treatment of atopic dermatitis (AD). The Prescription Drug User Fee Act (PDUFA) action date has been extended by three months to September 21, 2021. The FD
June 11, 2021 10:20 UTC
Carter’s, Inc. Announces Participation at the Evercore ISI Consumer & Retail Summit
Carter’s, Inc. Announces Participation at the Evercore ISI Consumer & Retail Summit June 11, 2021 10:20 UTC Carter’s, Inc. Announces Participation at the Evercore ISI Consumer & Retail Summit ATLANTA--(BUSINESS WIRE)-- Carter’s, Inc. (NYSE:CRI), the largest branded marketer in North America of apparel exclusively for babies and young children, announced today that the Company will present at the virtual Evercore ISI Consumer & Retail Summit on Tuesday, June 15, 2021 at 12:30 p.m. Eastern Daylight Time. A live webcast of the presentation will be available on the Investor Relations section of the Company’s website at ir.carters.com. About Carter’s, Inc. Ca
June 11, 2021 07:01 UTC
Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021
Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021 June 11, 2021 07:01 UTC Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021 - Exploratory biomarker analyses suggest possible cardiac disease improvements and renal response - BORDENTOWN, N.J. & BOSTON--(BUSINESS WIRE)-- Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced new Phase 2 safety and tolerability data for CAEL-101, a potentially first-in-class amy
June 11, 2021 13:00 UTC
Brit + Co Launches Selfmade Season Four in Collaboration with Office Depot
Brit + Co Launches Selfmade Season Four in Collaboration with Office Depot June 11, 2021 13:00 UTC Brit + Co Launches Selfmade Season Four in Collaboration with Office Depot Virtual Startup School That Has Helped Female Entrepreneurs Launch Hundreds of Mission-Driven Companies Kicks Off Summer Session on Monday, June 28 SAN FRANCISCO & BOCA RATON, Fla.--(BUSINESS WIRE)-- Brit + Co and Office Depot today announced that Office Depot will continue to provide opportunities for female entrepreneurs with the company’s sponsorship of the fourth cohort of Selfmade, Brit + Co’s 10-week virtual startup school for women. The course is hosted by Brit + Co founder Brit Morin, with
June 11, 2021 07:00 UTC
Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia
Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia June 11, 2021 07:00 UTC Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia Results showed treatment with Reblozyl plus best supportive care improved anemia in 77% of patients compared to placebo Reblozyl was generally well tolerated and improvements in hemoglobin correlated with improved patient-reported outcomes over a continuous 12-week interval In the study, 89.6% of p

Execution time: 0.3614 seconds
Layout: desktop